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OBJECTIVES This study was designed to compare the effects of inhaled carbon monoxide (CO),
administered to achieve concentrations similar to those found in cigarette smoking, with the
effects of cigarette smoking and air inhalation on heart rate and blood pressure, catecholamine
release, platelet activation and C-reactive protein (CRP), a marker of inflammation.
BACKGROUND Carbon monoxide may contribute to smoking-induced cardiovascular disease. Exposure to
environmental CO has been associated with increased cardiovascular morbidity and mortality.
Animal and in vitro studies suggest that CO may contribute to atherosclerosis and endothelial
injury. There is conflicting evidence about the hemodynamic consequences of exposure to CO
and its role in platelet activation.
METHODS In a single-blind, crossover design, 12 healthy smokers inhaled CO at 1,200 ppm to 1,500
ppm to simulate CO intake from cigarette smoking, inhaled air on a similar schedule and
smoked 20 cigarettes per day, each for seven days. Mean carboxyhemoglobin was 5  1% on
CO treatment, 6  1% while smoking and 0.4  0.2% on air inhalations.
RESULTS There was no difference in blood pressure between the treatments. Mean heart rate was
higher during cigarette smoking compared with CO and air inhalations (75 beats/min vs. 66
beats/min; p  0.05). Plasma levels of platelet factor 4 and CRP and urine epinephrine and
norepinephrine were higher while smoking, with no effect of CO compared with air.
CONCLUSIONS Carbon monoxide administered under conditions similar to those of cigarette smoking had no
significant effect on blood pressure, heart rate, plasma catecholamines, platelet aggregation or
CRP. The short-term chronotropic effect, adrenergic-activating, platelet-activating and
CRP-increasing effects of smoking in healthy smokers are probably due to components of
cigarette smoke other than CO. (J Am Coll Cardiol 2001;38:1633–8) © 2001 by the
American College of Cardiology
Cigarette smoking is a well-known risk factor for cardio-
vascular disease, including ischemic heart disease. Cigarette
smoke consists of many chemicals, including nicotine, tar
with its many carcinogens, and gaseous compounds includ-
ing carbon monoxide (CO). Nicotine has well known acute
and chronic cardiovascular effects, mainly through sympa-
thetic activation, although the contribution of nicotine per
se in cardiovascular morbidity and mortality induced by
cigarette smoking is uncertain (1).
Carbon monoxide is suspected to play a major role in
cigarette smoke-induced cardiovascular diseases. There is
epidemiologic evidence that workers exposed to high CO
concentrations have more cardiovascular morbidity and
mortality than the expected rate in the population (2–4),
and a positive correlation between ambient air CO concen-
trations and cardiovascular hospital admissions has been
reported (5,6).
The main mechanism by which CO causes heart disease
is production of hypoxia. The effects of CO are more
profound in the myocardium than in peripheral tissues
because of very high oxygen extraction by the myocardium
at rest (7,8). Carbon monoxide may also have direct myo-
cardial effects. In isolated rat hearts, CO caused a greater
decrease in heart rate and pulse pressure compared to the
same degree of anoxia produced by the inhalation of
nitrogen (9).
Carbon monoxide exposure has been implicated in the
process of atherosclerosis. Studies in rabbits and monkeys
have reported that exposure to CO produced an accumula-
tion of cholesterol in the aorta and coronary arteries and
endothelial damage (10–13). Similar effects have been
demonstrated in vitro. Arteries perfused with CO had a
higher uptake of cholesterol compared with controls (14).
Vascular wall injury has been linked to both abnormal lipid
infiltration and increased capillary permeability (15). In
humans, CO has been well known to have detrimental
effects in the presence of ischemic heart or peripheral
vascular disease. Individuals with ischemic heart disease
have a decrease in exercise capacity and a lower threshold for
ischemia after exposure to low levels of CO that are
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comparable to those observed in light to moderate smokers
(16,17).
The hemodynamic and hormonal effects of CO are less
clear (18). Research involving various animals—dogs, goats,
rabbits and rats—and different doses of CO administration
has been reported. Some of the studies were confounded by
the effects of anesthesia on the animals. In some cases, CO
increased heart rate, whereas in others CO produced no
change or bradycardia (8,19–23). In humans, the results
have also been variable (24–26). Some studies have found
that CO decreases blood pressure; others found no change
(20,22,27,28).
Cigarette smoking is known to potentiate platelet aggre-
gation and thrombosis (29,30). Several studies indicate that
nicotine does not cause platelet aggregation (30–32). The
role of CO in platelet aggregation is not completely clear,
but some studies have indicated increased platelet activation
and aggregation (33,34).
Inflammation appears to play a role in the pathophysiol-
ogy of coronary heart disease (35). C-reactive protein
(CRP) is an acute-phase reactant that reflects inflammatory
activity in the cardiovascular system and is a predictor of the
risk of future cardiovascular events (36,37). Cigarette smok-
ing is associated with increased levels of CRP (36,38).
Carbon monoxide exposure might also influence an inflam-
matory response to smoking (39).
Thus, although there is convincing evidence from human
studies that CO can exacerbate ischemic heart disease, the
acute hemodynamic and hormonal effects of CO are less
clear. An understanding of how CO affects the cardiovas-
cular system is important for an understanding of effects of
cigarette smoking as well as possible effects of air pollution.
The aim of our study was to compare the effects of sustained
exposure to CO (seven days), in concentrations similar to
those of cigarette smokers, with the effects of cigarette
smoking and air inhalation on heart rate, blood pressure,
catecholamine release, platelet activation and CRP, a
marker of inflammation.
METHODS
Subjects. The subjects were 12 healthy male smokers aged
27 to 47 years. The average usual number of cigarettes
smoked per day was 28 (range 18 to 40). The mean baseline
plasma cotinine level was 316 ng/ml (range 184 ng/ml to
603 ng/ml). The average Fagerstro¨m dependence question-
naire score was 7.6 (range 6 to 10), consistent with a high
level of dependence.
Written informed consent was obtained from all subjects
and the study protocol was approved by the Committee on
Human Research at the University of California, San
Francisco.
Experimental protocol. The study was conducted in the
General Clinical Research Center at San Francisco General
Hospital Medical Center over 21 days. The study was of a
crossover design with three treatments: inhalation of CO,
cigarette smoking and inhalation of air. Each treatment was
administered for seven days without additional washout
days. Because of the relatively short half-lives of nicotine
(averaging 2 h) and CO (averaging 3 h to 6 h), the first three
days of each treatment were judged to be an adequate time
interval to allow washout of previous treatment effects. The
smoking treatment could not be blinded, but the inhalation
treatments were single-blinded for the subjects. In inhala-
tion treatments, subjects inhaled CO or air from 1-l bags,
once every minute for 10 min, to simulate smoke inhalation
from cigarette smoking. The inhalations were repeated 20
times a day, once every 45 min from 8 AM to midnight. The
concentration of CO (in air) was 1,200 ppm for the first
three subjects, and 1,500 ppm for the others.
In the smoking treatment, the subjects smoked 20 ciga-
rettes per day, one every 45 min. Expired CO levels were
monitored daily at 8 AM and 12 PM, and blood carboxyhe-
moglobin (COHb) concentration measured on day 5 every
4 h between 8 AM and midnight. On day 3 of each
treatment, blood pressure and heart rate were recorded for
24 h using an ambulatory blood pressure monitor (Accu-
tracker, SunTech Industries, Raleigh, North Carolina). On
day 4 of each treatment, blood was collected at 8 AM and
12 PM for determination of white blood cell count, CRP,
plasma platelet factor 4 (PF4), plasma beta thromboglobulin
(BTG) and plasma catecholamines. Urine was collected for
24 h for measurement of catecholamines. On days 5 and 6
of each treatment, a 30-min intravenous infusion of 3,
3-dideuteronicotine and 2,4,5,6-tetradeuterocotinine and
oral doses of caffeine and clorzoxazone were administered to
determine the effect of CO on nicotine and drug metabo-
lism. The results of the metabolism study are reported
elsewhere (40).
Biochemical analysis. Carboxyhemoglobin was measured
using a Ciba-Corning-2500 co-oximeter. Plasma concen-
trations of nicotine and cotinine were measured by gas
chromatography with nitrogen phosphorus detection
(NPD) using 5-methyl-nicotine and 1-methyl-5-(3-
pyridyl)-pyrrolidin-2-one (ortho-cotinine) as internal stan-
dards. The method is essentially identical with a published
gas chromatography-mass spectrometry method (41), with
the exception that NPD is used instead of mass spectrom-
etry for detection and that different internal standards are
used. Urinary catecholamines were analyzed by high-
performance liquid chromatography using an electrochem-
Abbreviations and Acronyms
AUC  area under the concentration or
response-time curve
BTG  beta thromboglobulin
CO  carbon monoxide
COHb  carboxyhemoglobin
CRP  C-reactive protein
ELISA  enzyme-linked immunosorbent assay
NPD  nitrogen phosphorus detection
PF4  platelet factor 4
1634 Zevin et al. JACC Vol. 38, No. 6, 2001
Cardiovascular Effects of CO and Cigarette Smoking November 15, 2001:1633–8
ical detector (42). Plasma catecholamines were assayed by a
modification of the method of Anton and Sayre, as de-
scribed previously (43). Plasma CRP was measured in
platelet-poor plasma with enzyme-linked immunosorbent
assay (ELISA) method using a commercial kit (Hemagen
Diagnostics, Inc., Waltham, Massachusetts). Platelet factor
4 and BTG were assayed in platelet-poor plasma with
ELISA using commercial kits (Asserachrom PF4 and As-
serachrom BTG from Diagnostica Stago, Asnie`res-sur-
Seine, France).
Data analysis. Areas under the response-time curves
(AUC) for blood pressure and heart rate, and areas under
concentration-time curves for nicotine were computed using
the trapezoidal method. The mean values for 24 h were
calculated as AUC7AM–7AM/24 h. For blood pressure and
heart rate, mean daytime (7 AM to 10 PM inclusive) and
nighttime (11 PM to 6 AM inclusive) values were calculated
as: AUC7AM–10PM/15 h and AUC11PM–7AM/9 h, respectively.
Treatment effects were compared by repeated-measures
analysis of variance. Data were log-transformed when vari-
ance across treatments was not homogeneous. Post-hoc
comparisons were made using the Tukey test. The power of
the study to detect a difference of about 25%, which is
typically taken as clinically meaningful, varied from 65% to
95% depending on the measure.
RESULTS
Six subjects underwent the sequence CO/smoking/air and
six subjects the reverse. The levels of COHb throughout the
day were similar in the CO inhalation and cigarette smok-
ing conditions. Mean ( SD) COHb levels were 5 1% on
CO inhalation treatment, 6  1% on smoking treatment
and 0.4  0.2% on air inhalation treatment (Fig. 1). Plasma
nicotine concentrations averaged 5 ng/ml to 24 ng/ml
throughout the day during cigarette smoking, and1 ng/ml
in the no-smoking conditions. Plasma cotinine concentra-
tion averaged 270 ng/ml in the smoking condition.
There was no effect of CO inhalations on mean heart
rate. Cigarette smoking caused a significant increase in heart
rate compared to other treatments including overnight
(Table 1). On all treatments, daytime heart rate was
significantly higher than nighttime (Table 1). There were
no differences in either systolic or diastolic blood pressure
across the treatments. For each treatment, daytime values
for blood pressure were significantly higher than nighttime
values (Table 1).
Plasma epinephrine (mean  SD) levels were higher
during cigarette smoking compared to the other treatments
(25  12 pg/ml; 19  10 pg/ml and 19  8 pg/ml on
cigarette smoking, CO and air inhalations, respectively), but
the difference was not statistically significant. Plasma nor-
epinephrine levels (mean  SD) also trended higher on the
smoking treatment (205  92 pg/ml; 166  61 pg/ml and
182  120 pg/ml, on cigarette smoking, CO and air
inhalations, respectively). Urine 24 h excretion of norepi-
nephrine and epinephrine were significantly higher on
cigarette smoking, and there was no effect of CO (Fig. 2).
Plasma CRP and PF4 were significantly higher on cigarette
smoking (p  0.05), and there was no significant difference
between CO and air treatments. The CRP data are shown
in Figure 3. Platelet factor 4 values averaged 3.6  1.6
Figure 1. Mean ( SEM) carboxyhemoglobin (COHb) time course on
day 5 of carbon monoxide inhalations (CO), cigarette smoking (CS) and
air inhalations (AIR). Smoking and inhalation treatments started at 8 AM
and were administered every 40 min till midnight.
Table 1. The Effect of CO, CS and Air Inhalation on HR and
Blood Pressure
CO CS Air
HR (beats/min) 24-h mean 66  6 75  7* 67  6
Day 69  6 79  7* 70  6
Night 61  7 67  7* 61  6
SBP (mm Hg) 24-h mean 120  8 124  9 120  9
Day 124  19 129  9 123  11
Night 113  6 115  13 112  9
DBP (mmHg) 24-h mean 66  6 68  6 67  7
Day 69  7 72  7 69  7
Night 62  5 63  6 62  7
Mean  SD. *p  0.05 compared to carbon monoxide (CO) or air.
CS  cigarette smoking; DBP  diastolic blood pressure; HR  heart rate;
SBP  systolic blood pressure.
Figure 2. Mean ( SEM) urinary levels of epinephrine, norepinephrine,
and dopamine on carbon monoxide inhalations (CO), cigarette smoking
(CS) and air inhalations (AIR), n  10. *p  0.05. Urine was collected for
24 h. The levels while smoking cigarettes were significantly (p  0.05)
higher compared to other treatments.
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IU/ml, 5.0  2.6 IU/ml and 3.9  1.2 IU/ml in the
CO, smoking and air conditions, respectively. Beta
thromboglobulin also tended to be higher on smoking
treatment, without any effect of CO inhalation.
DISCUSSION
We have developed an experimental CO intervention to
simulate the exposure of CO from cigarette smoking.
Average CO concentrations were similar during CO inha-
lation and cigarette smoking in our subjects compared with
breathing air alone. Carbon monoxide delivered in this way
had no effect on heart rate, catecholamine release, platelet
activation or CRP. Cigarette smoking had the expected
effects on these parameters.
Heart rate and blood pressure. Heart rate was signifi-
cantly higher with cigarette smoking compared to the other
treatments. Cardiac acceleration while smoking is well
known, and is mediated by nicotine via sympathetic neural
activation (44–46). In previous studies in humans, the
reported effects are variable: most reports concerned CO
poisoning and tachycardia was present (26,47), whereas in
moderate exposures with COHb up to 15%, no change in
heart rate was seen (24,28,48). Our study supports the latter
results.
Systolic and diastolic blood pressure did not differ across
the treatments. Acute exposure to CO in humans produces
a decrease in systemic vascular resistance (49). However,
prolonged exposure for eight days with COHb levels of 12%
did not result in any changes in blood pressure (50), and
acute exposures resulting in COHb levels of up to 20% did
not cause any change in blood pressure, at rest or during
exercise (25,28). Hausberg and Somers found that acute
exposure to CO inhalation did not have any effect on muscle
sympathetic nerve activity, forearm blood flow or blood
pressure or heart rate (48). Our results are in agreement with
those demonstrating no change at levels of COHb observed
in smokers.
Catecholamine release. We found significantly increased
levels of urinary epinephrine and norepinephrine levels
during cigarette smoking, but catecholamine excretion was
not affected by CO compared with air. Pankow and Ponsold
found a transient increase in urinary catecholamines in rats
after exposure to CO with COHb levels of 50%; however,
after continuous CO exposure this effect disappeared (51).
Our data indicate that CO does not contribute to the
elevated catecholamine levels found in cigarette smokers.
Platelet activation. Cigarette smoking is associated with
increased coagulation; both the platelet function and the
coagulation factors are affected (29,52–54). Cigarette smok-
ing, but not nicotine, has been shown to increase plasma
concentrations of PF4 and BTG (29,30). One possible
candidate for inducing platelet activation is CO. In dogs
with stenosed coronary arteries, non-tobacco burning ciga-
rettes caused the same rise in platelet activation and throm-
bus formation as tobacco-burning cigarettes (33). In human
in vitro studies, increasing COHb levels, but not nicotine,
were associated with increase in platelet aggregation (34).
We used the concentrations of the constituents of platelet
alpha-granules, PF4 and BTG, as markers for in vivo
platelet activation. We found increased levels of PF4 with
cigarette smoking but not with CO inhalations, compared
with air. Beta thromboglobulin was also higher with smok-
ing, but the differences did not reach statistical significance.
Thus, our data indicate that CO in the concentrations
found in cigarette smoke does not cause platelet activation.
Cigarette smoking is associated with an inflammatory
state, indicated by higher levels of CRP compared to
nonsmokers (36,38). The level of CRP is reported to
increase in relation to the number of pack-years of cigarette
smoking (38). The latter study suggested that CRP remains
elevated after smoking cessation, and is no different in
current smokers compared with former smokers. Our study
provides novel data indicating that within a few days of not
smoking, CRP levels decline significantly, indicating that
cigarette smoking has an acute effect to stimulate inflam-
mation.
We are unaware of data on the effects of inhalation of CO
on CRP or other inflammatory markers. However, CO is
released in inflammatory conditions, and the expression of
heme oxygenase, the enzyme that generates endogenous
CO, is associated with the suppression of inflammation
(39). Thus, one might expect that CO would have an
inhibitory effect on the inflammatory response. In the
present study, CO inhalation was associated with a CRP
level that was no different than that in the air inhalation
condition.
Conclusions. The results of our study indicate that inhaled
CO, delivered to healthy smokers in concentrations similar
to those in cigarette smoke, has little or no effect on heart
rate, blood pressure, catecholamine secretion or platelet
activation, at least with exposure for several days, compared
to inhalation of air. The effects of smoking on these
Figure 3. Mean ( SEM) plasma levels of C-reactive protein (CRP) on
carbon monoxide inhalations (CO), cigarette smoking (CS) and air
inhalations (AIR). Analysis of variance of log CRP revealed a significant
effect of cigarette smoking (*p  0.005). Differences were significant both
at 8 AM and 12 PM.
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parameters in healthy smokers are most likely due to other
constituents of cigarette smoke.
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